Allergan (NYSE: AGN) reported Q4 EPS of $3.90, $0.14 better than the analyst estimate of $3.76. Revenue for the quarter came in at $3.86 billion versus the consensus estimate of $3.77 billion.

GUIDANCE:

Allergan sees FY2017 EPS of $15.80-$16.30, versus the consensus of $16.01. Allergan sees FY2017 revenue of $15.5-15.8 billion, versus the consensus of $15.37 billion.

"2016 was a year of transformation for Allergan. We are now a branded biopharmaceutical leader, focused on delivering sustainable revenue growth, advancing our pipeline, maintaining industry leading margins and allocating capital to maximize shareholder return. In the fourth quarter of 2016, we delivered against these priorities. Our top global products and new launches powered revenue growth, including, but not limited to, BOTOX®, RESTASIS®, OZURDEX®, Fillers, LINZESS®, VRAYLAR™, VIBERZI®, KYBELLA® and Lo LOESTRIN®. Our R&D team continued to advance key programs and deliver FDA approvals for new products that change lives. And we made fast progress in our capital deployment program, enhancing short- and long-term value for our shareholders," said Brent Saunders, Chairman and CEO of Allergan.

"2017 is a pivotal year for Allergan and we are well-positioned to deliver growth through excellent execution. We have growing products and franchises, with nine product launches planned in 2017. Our Open Science pipeline is advancing innovative, high-value treatments for patients, including our six \'stars\' entering or currently in phase 3 development. And our operational excellence and capital deployment initiatives will support our continued growth and enhance shareholder value," added Saunders.

"I thank our 16,000 global colleagues who continue to Be Bold. They are delivering new ideas that allow us to build strong bridges with customers, act fast, and drive results for Allergan. And they are focused on advancing innovative new treatments across our therapeutic areas that can make a profound impact on global health and patient care," added Saunders.

For earnings history and earnings-related data on Allergan (AGN) click here.